Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

3.666 -0.054 (-1.47%)
Streaming Delayed Price Updated: 12:25 PM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) Posts Narrower Q3 2025 Loss, Advances Gene Therapy Pipeline ↗
Rocket Pharma posts a narrower-than-expected Q3 2025 loss. Key gene therapy pipeline advances include an FDA-accepted BLA for KRESLADI™ and a lifted clinical hold for its Danon Disease program. 
Via Chartmill
News headline image
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline. 
Via Benzinga
News headline image
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock ↗
FDA accepts Rocket Pharmaceuticals' resubmission for Kresladi gene therapy in severe LAD-I, with a decision expected by March 2026. 
Via Benzinga
News headline image
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy ↗
The company said that the decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya. 
Via Stocktwits
News headline image
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact. 
Via Benzinga
News headline image
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Coty, Bilibili, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Nordson Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Wednesday? ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients ↗
The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys. 
Via Stocktwits
Topics Death
News headline image
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. 
Via Chartmill
News headline image
TJX Posts Better-Than-Expected Earnings, Joins Rocket Pharmaceuticals, Guess? And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy ↗
Rocket Pharmaceuticals shares rise after FDA clears its pivotal RP-A501 trial for Danon disease with adjusted dosing and updated treatment protocol. 
Via Benzinga
News headline image
Wednesday's pre-market session: top gainers and losers ↗
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Is Rocket Pharma Stock Up 15% Pre-Market Today? ↗
The U.S. Food and Drug Administration has lifted the clinical hold on the company’s mid-stage study of RP-A501 for the treatment of Danon disease. 
Via Stocktwits
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Levi &amp; Korsinsky Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.